VCM
JBIO

Versant Capital Management’s Jade Biosciences JBIO Stock Holding History

Versant Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1K Hold
905
– – ﹤0.01% 1926
2026
Q1 		$12.7K Buy
905
+512
+130% +$7.41K ﹤0.01% 2033
2025
Q4 		$6.06K Buy
+393
New +$4.61K ﹤0.01% 2177

Other funds holding JBIO

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
AFC
Ares Financial Consulting Calabasas, California $139M AUM
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HFS
Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return

Versant Capital Management's JBIO Position: Q2 2026 in Review

Versant Capital Management held its Jade Biosciences (JBIO) position steady in Q2 2026 at 905 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1926.

Versant Capital Management first reported a position in JBIO in Q4 2025 and has held it in 3 quarters since. 9 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Versant Capital Management held 905 shares of Jade Biosciences worth $20.1K as of Q2 2026.
  • Versant Capital Management left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1926 holding.
  • Versant Capital Management first reported a position in Jade Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 9 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.